Annual Drug Patent Expirations for RYBELSUS
Rybelsus is a drug marketed by Novo and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug.
Drug patent litigation for RYBELSUS.
This drug has one hundred and eighteen patent family members in thirty countries.
The generic ingredient in RYBELSUS is semaglutide. One supplier is listed for this compound. Additional details are available on the semaglutide profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
